Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Aptahem enters agreement with international clinical CRO for phase 1 studies with Apta-1

Aptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to perform the upcoming phase 1 studies with Apta-1. By entering this agreement, which follows on the previous Start-Up Agreement, the plans for the phase 1 studies will continue and preparations for the application to the authorities can be initiated.Aptahem is developing Apta-1 as an acute treatment to prevent organ and tissue damages in patients with sepsis or other inflammatory critical conditions.

Secure Bittium Tough Mobile™ 2 Smartphones and Accessories Exhibited at the Astrid User Days Event

Press release Free for publication on May 17, 2022, at 12.00 p.m. (CEST +1) Secure Bittium Tough Mobile™ 2 Smartphones and Accessories Exhibited at the Astrid User Days Event Oulu, Finland, May 17, 2022 – Bittium will showcase its secure smartphones and solutions at the Astrid User Days event on May 18-19, 2022, in Brussels, Belgium. The event is held at LouvExpo, and the products that will be exhibited include the Bittium Tough Mobile™ 2 smartphones, Bittium Secure Suite™ back-end system, and accessories for the smartphone. At the Bittium stand, will be also showcased the use of

First patient randomized in Phase 2 trial in head and neck cancer

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the first patient has been randomized in the company’s proof-of-concept Phase 2 study in patients with squamous cell carcinoma of the head and neck (SCCHN) with the NOX 1 and 4 inhibitor, setanaxib.The trial is a randomized, placebo-controlled, double-blind, proof-of-concept Phase 2 study. It will investigate the effect of setanaxib 800 mg twice daily in conjunction with pembrolizumab 200mg IV, administered every 3 weeks (the standard treatment regimen for this immunotherapy), in

SLP completes another sale and lease back deal

SLP has today acquired a major logistics property in Nässjö, Svedjan 1. The property has a total lettable area of approximately 12,700 sqm. and is currently let to Industrilås i Nässjö AB with a nine-year lease. SLP will take possession of the property on 30 June 2022.The seller of the property is a company within the same group as Industrilås i Nässjö and the transaction has taken place off-market. The underlying property value is approximately SEK 68 million and the property generates a rental value of approxi­mately SEK 4.8 million which is 100 percent indexed.   “We are pleased to be

Scandinavian ChemoTech receives final patent approval in the EU for the tumour specific control unit in our TSE™ platform

The Company has received the final approval for its EU patent which includes the tumour specific control unit and safety features that are crucial for our TSE platform. The innovation is designed to reduce the side effects which normally occur with older electroporation and ablative technologies.This patent further strengthens ChemoTech’s TSE technology and protects the crucial control unit that generates the unique TSE pulse. The control unit helps the treating physicians of both IQwave™ and vetIQure™ to reduce necros[1] and improve apoptosis[2].   The concept of TSE is to establish

Repurchase of NCC Series B shares in week 19, 2022

During the period May 11 – May 13, 2022, NCC (LEI-code 213800WRGLW3CY4MHW53) repurchased a total of 264,980 own Series B shares (ISIN: SE0000117970) under the framework of the repurchase program that the Board have decided.The repurchases are part of the repurchase program of a maximum of 10 percent of Series B shares for a total of not more than SEK 1.5 bn that NCC announced on April 27, 2022. The repurchase program extends from May 11, 2022 until the 2023 Annual General Meeting and is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the

The Swedish FSA maps Swedbank IT-incident

The Swedish FSA has today notified Swedbank that the authority intends to map the events that resulted in incorrect account statements for customers.Swedbank has continuously, during and after the disturbance, informed the Swedish FSA according to established procedure. "Swedbank suffered from a substantial IT-disturbance during the night between April 28 and 29 which affected our customers. This is very serious, and we take forceful measures to prevent this from happening again. We welcome the Swedish FSA’s initiative to map the events, says Jens Henriksson," President and CEO of

Background information on intra-group arrangement

On this date, Egmont Holding Oy (“Egmont Holding”) is performing a transfer of all shares in Nitro Games Oyj held by Egmont Holding to Nordisk Games A/S ("Nordisk Games"). The purpose of this arrangement is to simplify the holding structure of the Egmont group's gaming activities. Both Egmont Holding and Nordisk Games are (indirectly) wholly-owned by Egmont International Holding A/S and, thus, the ultimate ownership of the shares will not change as part of this intra-group arrangement.

BioStock: Sprint Bioscience increases innovation power

Huddinge-based Sprint Bioscience has a long-standing collaboration with Associate Professor Julian Walfridsson to find new target proteins that may be relevant in the treatment of acute myeloid leukemia. Last autumn, the project was awarded a research grant of 2.5 MSEK and now the collaboration is further expanded.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-increases-innovation-power/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Cardo Health appoints Oriel Carew as Chief Growth Officer

May 17 2022 Oriel Carew is joining Cardo Health as Chief Growth Officer to lead the company’s growth on its mission to democratise access to healthcare in emerging markets. Oriel will be responsible for driving growth in co-owned companies and leading expansion into new markets through developing and executing investment strategies.Combining deep expertise in healthcare, business management and strategy, Oriel is driven by a passion to improve healthcare delivery. Prior to joining Cardo Health, she was Director of Strategy and Planning at HCA Healthcare UK, where she led development and

OptiGroup acquires Scholte Medical in the Netherlands

OptiGroup has acquired 100% of the shares of Scholte Medical BV in the Netherlands. Scholte Medical, with revenues of approximately EUR 16.5 million, is a Dutch full-service distributor of high-quality medical equipment and supplies. The acquired company will become part of OptiGroup’s Hygos business area and will continue to operate under its current brands Daxtrio and Mediost. The purchase price has not been disclosed. Through the acquisition, OptiGroup will further strengthen its Benelux position in medical supplies to the professional healthcare sector. “We are pleased to welcome

Fortum Corporation: Managers' transactions – Merina Eveliina Dahl

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Dahl, Merina Position: Other senior manager Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124109_148 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 166 Unit price: 16.8189 EUR

Fortum Corporation: Managers' transactions – Mikael Rönnblad

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Rönnblad, Mikael Position: Other senior manager Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516125937_154 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 14 Unit price: 16.8189 EUR

New financial targets to be presented at Sandvik’s Capital Markets Day

Today, at the Capital Markets Day in Stockholm, Sweden, Stefan Widing, President and CEO and Cecilia Felton, Executive Vice President and CFO, will cover Sandvik’s shift to growth focus areas, key achievements and the ambitions going forward, including new financial targets, for the Sandvik Group.   Business area management will also share their achievements since the strategy was presented at Sandvik’s previous Capital Markets Day, in November, 2020, and outline their respective strategic priorities for a continued successful execution.   “We are delivering on our shift to

Sandvik implements structural measures to support resilience ambitions

Sandvik is continuously reviewing options of how to reduce complexity and increase competitiveness, efficiency and flexibility to support the strategic direction of the Group. This becomes even more important with an active inorganic growth agenda. Sandvik’s most recent program of restructuring initiatives was announced in 2020, with savings now fully realized. Sandvik has now identified and decided to implement new structural measures, which will strengthen the platform going forward.   The new measures include consolidation of productions units, site closures and optimizing the

Fortum Corporation: Managers' transactions – Bernhard Günther

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Günther, Bernhard Position: Chief Financial Officer Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124109_150 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 148 Unit price: 16.8189 EUR

Fortum Corporation: Managers' transactions – Markus Rauramo

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Rauramo, Markus Position: Chief Executive Officer Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124109_152 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 202 Unit price: 16.8189 EUR

Fortum Corporation: Managers' transactions – Nebahat Albayrak

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Albayrak, Nebahat Position: Other senior manager Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124109_151 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 148 Unit price: 16.8189 EUR

Fortum Corporation: Managers' transactions – Nora Steiner-Forsberg

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Steiner-Forsberg, Nora Position: Other senior manager Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124109_147 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 97 Unit price: 16.8189 EUR

Fortum Corporation: Managers' transactions – Per Langer

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Langer, Per Position: Other senior manager Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124106_146 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 52 Unit price: 16.8189 EUR Aggregated

Fortum Corporation: Managers' transactions – Simon-Erik Ollus

FORTUM CORPORATION STOCK EXCHANGE RELEASE 17 MAY 2022 AT 11:00 EEST Release category: Managers’ transactions Person subject to the notification requirement Name: Ollus, Simon-Erik Position: Other senior manager Issuer: Fortum Corporation LEI: 635400IUIZZIUJSAMF76 Notification type: INITIAL NOTIFICATION Reference number: 635400IUIZZIUJSAMF76_20220516124109_149 Transaction date: 2022-05-13 Venue: XHEL Instrument type: SHARE ISIN: FI0009007132 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 193 Unit price: 16.8189 EUR

3 additional companies to present at the BioStock Life Science Spring Summit

On June 8-9, it is finally time for BioStock Life Science Spring Summit 2022, where companies from a wide range of therapeutic areas will present their projects and innovations, in a packed program that also offers valuable insights from investment experts and industry profiles. Today, we reveal three new companies that will present at the Spring Summit!The event will be broadcasted on the BioStock website and on our YouTube channel. You can also access the event through our social media platforms. Today, we reveal three new companies that will present at the BioStock Life Science Spring

BioStock: Focus on company split for Respiratorius during Q4

Lund-based Respiratorius is currently undergoing an extensive transformation where the company’s two development projects are being separated. That process set the tone for the company’s report for the fourth quarter of the fiscal year 2021/2022, which this time included four months, instead of the customary three. BioStock contacted Respiratorius’ CEO Johan Drott to find out more about what is going during this transformative time for the company.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/focus-on-company-split-for-respiratorius-during-q4/This is a press

BioStock: Ultimovacs keeps delivering in Q1

Q1 saw Norwegian immuno-oncology company Ultimovacs advance on a number of fronts. The company’s clinical programmes with universal cancer vaccine UV1 and adjuvant platform TET have continued to progress steadily. Moreover, milestones were reached at the preclinical level as well as the intellectual property level.Read the article at biostock.se : https://www.biostock.se/en/2022/05/ultimovacs-keeps-delivering-in-q1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

There are no items matching the current filter
There are no more items matching the current filter
Back to top